Full-Time

Scientific Business Analyst

Specialist, Large Molecule Discovery, Research Informatics

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

CA$109k - CA$136k/yr

Mid, Senior, Expert

Burnaby, BC, Canada

In Person

Category
Project Management
Business Development
Business & Strategy
Required Skills
Machine Learning
Data Analysis
Requirements
  • Doctorate Degree
  • Master’s degree with 4 - 6 years of experience in Computer Science, IT, Computational Chemistry, Computational Biology/Bioinformatics or related field
  • Bachelor’s degree with 7 - 9 years of experience in Computer Science, IT, Computational Chemistry, Computational Biology/Bioinformatics or related field
  • Diploma with 10 - 12 years of experience in Computer Science, IT, Computational Chemistry, Computational Biology/Bioinformatics or related field
Responsibilities
  • Function as a Scientific Business Systems Analyst within a Scaled Agile Framework (SAFe) product team
  • Serve as a liaison between global Research Informatics functional areas and global research scientists, prioritizing their needs and expectations
  • Manage a suite of custom internal platforms, commercial off-the-shelf (COTS) software, and systems integrations
  • Lead the Large Molecule Discovery technology ecosystem and ensure that the platform meets the requirements for data analysis and data integrity
  • Translate complex scientific and technological needs into clear, actionable requirements for development teams
  • Develop and maintain a product roadmap that clearly outlines the planned features and enhancements, timelines, and milestones
  • Identify and manage risks associated with the systems, including technological risks, scientific validation, and user acceptance
  • Develop documentations, communication plans and training plans for end users
  • Ensure scientific data operations are scoped into building Research-wide Artificial Intelligence/Machine Learning capabilities
  • Ensure operational excellence, cybersecurity and compliance
  • Collaborate with geographically dispersed teams, including those in the US and other international locations
  • Foster a culture of collaboration, innovation, and continuous improvement.
Desired Qualifications
  • 5+ years of experience in implementing and supporting biopharma scientific software platforms.
  • Demonstrated expertise in a scientific domain area and related technology needs
  • Experience with writing user requirements and acceptance criteria in agile project management systems such as JIRA
  • Experience in configuration and administration of LIMS/ELN platforms (e.g. Benchling), Discovery software tools (e.g. Geneious, Genedata Screener) and Instrument Automation and Analysis platforms
  • Experience using platforms such as Spotfire, Tableau, Power BI, etc., to build dashboards and reports and understanding of basic data querying using SQL, Databricks, etc.
  • Experience leading the implementation of scientific software platforms, Electronic Lab Notebook (ELN), or Laboratory Information Management Systems (LIMS)
  • Knowledge of the antibody discovery design, make, test, and analyze cycle.
  • Experience in AI and machine learning for drug discovery research and preclinical development
  • Experience with leveraging LLM tools to accelerate software development processes.
  • Experience with cloud (e.g. AWS) and on-premise infrastructure
  • In-depth knowledge of Agile processes and principles for coordinated solutions and teams via SAFe
  • Experience in establishing business partnerships and IS governance practices involving senior business stakeholders
  • Knowledge of business analysis best practices, DevOps, Continuous Integration, and Continuous Delivery methodology
  • SAFe for Teams certification

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen stands out from competitors by reinvesting a large portion of its earnings into research and development, ensuring a strong pipeline of new treatments. The goal of Amgen is to improve patient care and outcomes through the discovery of effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.